NDAORALTABLET
Approved
Nov 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HETRAZAN (diethylcarbamazine citrate) is an oral small-molecule antifilarial agent approved in 1950 for treating parasitic infections caused by filarial worms. It works by immobilizing microfilariae, making them susceptible to host immune clearance. This legacy product addresses neglected tropical diseases primarily in resource-limited settings.
LOE Approaching
Declining franchise nearing patent expiry with minimal linked job openings suggests a small, stable team focused on managed decline and compliance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HETRAZAN offers minimal direct career advancement in the United States market but may provide valuable experience in global health, emerging market operations, and managed decline strategy. This role is best suited for professionals early in their careers or those with a specific focus on neglected tropical diseases and public health impact.
Regulatory Affairs
Worked on HETRAZAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.